For Mounjaro, these include nausea (1229% of patients depending on dose), diarrhea (1216%), vomiting (59%), constipation (67%), and abdominal pain or discomfort
The primary goal of this article is to emphasize the extensive benefits of using GLP-1RAs in treating a broad spectrum of diseases, such as obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer
Psychiatry 15:1347178
Brain Dev 33:512517 Sakai E, Yamanaka G, Kawashima H, Morishima Y, Ishida Y, Oana S, Miyajima T, Shinohara M, Saitoh M, Mizuguchi M (2013) A case of recurrent acute encephalopathy with febrile convulsive status epilepticus with carnitine palmitoyltransferase II variation
and Schork, A